John K. Ramage

Denmark Hill
Hill, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 103 publications

Survival of carcinoid lung neuroendocrine tumours after surgical resection: A retrospective audit of 633 cases over 26 years.

Survival of carcinoid lung neuroendocrine tumours after surgical resection: A retrospective audit of 633 cases over 26 years.

Journal: Tumori
Published: August 20, 2026

Epidemiology and Overall Survival of De Novo and Transformed Neuroendocrine Prostate Cancer: A Two-Nation Population-Based Study of 1,465 Patients from the United States and England.

Epidemiology and Overall Survival of De Novo and Transformed Neuroendocrine Prostate Cancer: A Two-Nation Population-Based Study of 1,465 Patients from the United States and England.

Journal: Endocrine-related cancer
Published: May 26, 2026

Developing thresholds for clinical importance for the EORTC Quality of Life Questionnaire - Elderly 14 (QLQ-ELD14) to improve its interpretation in clinical practice and research.

Developing thresholds for clinical importance for the EORTC Quality of Life Questionnaire - Elderly 14 (QLQ-ELD14) to improve its interpretation in clinical practice and research.

Journal: Journal of geriatric oncology
Published: April 14, 2026

Urine 5-HIAA and quality of life in neuroendocrine neoplasia. Is there an association?

Urine 5-HIAA and quality of life in neuroendocrine neoplasia. Is there an association?

Journal: Rare tumors
Published: January 18, 2026

Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial.

Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial.

Journal: ESMO open
Published: January 12, 2026

Hemicolectomy or appendectomy for appendiceal neuroendocrine tumours sized 1-2 cm? A retrospective population-based study of 1514 patients.

Hemicolectomy or appendectomy for appendiceal neuroendocrine tumours sized 1-2 cm? A retrospective population-based study of 1514 patients.

Journal: Journal of neuroendocrinology
Published: November 06, 2025

Usefulness of plasma bile acid profile as a prognostic biomarker for drug-induced liver injury.

Usefulness of plasma bile acid profile as a prognostic biomarker for drug-induced liver injury.

Journal: EBioMedicine
Published: October 25, 2025

Metastatic neuroendocrine lesions in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH): a narrative review and case series.

Metastatic neuroendocrine lesions in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH): a narrative review and case series.

Journal: Endocrine oncology (Bristol, England)
Published: October 17, 2025

Evaluation and enhancement of the prognostic ability of the eighth edition of TNM staging in cutaneous malignant melanoma: a population-based study, using machine learning, of 111 871 patients.

Evaluation and enhancement of the prognostic ability of the eighth edition of TNM staging in cutaneous malignant melanoma: a population-based study, using machine learning, of 111 871 patients.

Journal: The British journal of dermatology
Published: August 04, 2025

Survival following resection of 10,244 lung neuroendocrine tumours: a population study.

Survival following resection of 10,244 lung neuroendocrine tumours: a population study.

Journal: Endocrine-related cancer
Published: July 17, 2025

Epidemiology of Neuroendocrine Neoplasia Worldwide: A Review of the Literature (2012-2022).

Epidemiology of Neuroendocrine Neoplasia Worldwide: A Review of the Literature (2012-2022).

Journal: Neuroendocrinology
Published: July 14, 2025

Epidemiology and Health Impacts of Neuroendocrine Tumours.

Epidemiology and Health Impacts of Neuroendocrine Tumours.

Journal: Neuroendocrinology
Published: July 06, 2025
Showing 1-12 of 103

Last Updated: 09/26/2026